Gonçalo J. M. Cabrita

Gonçalo J. M. Cabrita

Auto-generated profile, based on publicly available information

Gonçalo J. M. Cabrita

Institute of Biotechnology and Bioengineering, Centre for Biological and Chemical Engineering, Instituto Superior Técnico, Av. Rovisco Pais, Lisboa 1049-001, Portugal

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2000 in Blood
Verified
Journal Article
Open access
PCPhilipp le Coutre
Philipp le Coutre
ETElena Tassi
Elena Tassi
MVMarileila Varella-Garcia
Marileila Varella-Garcia
RBRossella Barni
Rossella Barni
LMLuca Mologni
Luca Mologni
CGCarlo Gambacorti-Passerini
Carlo Gambacorti-Passerini
The 2-phenylaminopyrimidine derivative STI571 has been shown to selectively inhibit the tyrosine kinase domain of the oncogenicbcr/abl fusion protein. The activity of this inhibitor has been demonstrated so far both in vitro with bcr/abl expressing cells derived from leukemic patients, and in vivo on nude mice inoculated with bcr/abl positive cells. Yet, no information is available on whether leukemic cells can develop resistance to bcr/ablinhibition. The human bcr/abl expressing cell line LAMA84 was cultured with increasing concentrations of STI571. After approximately 6 months of culture, a new cell line was obtained and named LAMA84R. This newly selected cell line showed an IC50 for the STI571 (1.0 μM) 10-fold higher than the IC50 (0.1 μM) of the parental sensitive cell line. Treatment with STI571 was shown to increase both the early and late apoptotic fraction in LAMA84 but not in LAMA84R. The induction of apoptosis in LAMA84 was associated with the activation of caspase 3–like activity, which did not develop in the resistant LAMA84R cell line. LAMA84R cells showed increased levels of bcr/abl protein and mRNA when compared to LAMA84 cells. FISH analysis with BCR- and ABL-specific probes in LAMA84R cells revealed the presence of a marker chromosome containing approximately 13 to 14 copies of the BCR/ABL gene. Thus, overexpression of the Bcr/Abl protein mediated through gene amplification is associated with and probably determines resistance of human leukemic cells to STI571 in vitro.

18 October 2000 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
CGCarlo Gambacorti-Passerini
Carlo Gambacorti-Passerini
RBRossella Barni
Rossella Barni
PCPhilipp le Coutre
Philipp le Coutre
MZMassimo Zucchetti
Massimo Zucchetti
GCGonçalo Cabrita
Gonçalo Cabrita
Maurizio D'IncalciMaurizio D'Incalci
Maurizio D'Incalci
Background: Chronic myeloid leukemia is caused by a chromosomal translocation that results in an oncogenic fusion protein, Bcr-Abl. Bcr-Abl is a tyrosine kinase whose activity is inhibited by the antineoplastic drug STI571. This drug can cure mice given an injection of human leukemic cells, but treatment ultimately fails in animals that have large tumors when treatment is initiated. We created a mouse model to explore the mechanism of resistance in vivo. Methods: Nude mice were injected with KU812 Bcr-Abl+ human leukemic cells. After 1 day (no evident tumors), 8 days, or 15 days (tumors >1 g), mice were treated with STI571 (160 mg/kg every 8 hours). Cells recovered from relapsing animals were used for in vitro experiments. Statistical tests were two-sided. Results: Tumors regressed initially in all STI571-treated mice, but all mice treated 15 days after injection of tumor cells eventually relapsed. Relapsed animals did not respond to further STI571 treatment, and their Bcr-Abl kinase activity in vivo was not inhibited by STI571, despite high plasma concentrations of the drug. However, tumor cells from resistant animals were sensitive to STI571 in vitro, suggesting that a molecule in the plasma of relapsed animals may inactivate the drug. The plasma protein α1 acid glycoprotein (AGP) bound STI571 at physiologic concentrations in vitro and blocked the ability of STI571 to inhibit Bcr-Abl kinase activity in a dose-dependent manner. Plasma AGP concentrations were strongly associated with tumor load. Erythromycin competed with STI571 for AGP binding. When animals bearing large tumors were treated with STI571 alone or with a combination of STI571 and erythromycin, greater tumor reductions and better long-term tumor-free survival (10 of 12 versus one of 13 at day 180; P<.001) were observed after the combination treatment. Conclusion: AGP in the plasma of relapsed animals binds to STI571, preventing this compound from inhibiting the Bcr/Abl tyrosine kinase. Molecules such as erythromycin that compete with STI571 for binding to AGP may enhance the therapeutic potential of this drug.

1 May 2003 in Trends in Biotechnology
Verified
Journal Article
Closed access
GCGonçalo J.M. Cabrita
Gonçalo J.M. Cabrita
BFBruno Ferreira
Bruno Ferreira
CSCláudia Lobato da Silva
Cláudia Lobato da Silva
RGRaquel Madeira Gonçalves
Raquel Madeira Gonçalves
GAGraça Almeida-Porada
Graça Almeida-Porada
Joaquim M.S. CabralJoaquim M.S. Cabral
Joaquim M.S. Cabral

1 June 2009 in Ecological Engineering
Verified
Journal Article
Closed access
LDL.C. Davies
L.C. Davies
GCG.J.M. Cabrita
G.J.M. Cabrita
Renata FerreiraRenata Ferreira
Renata Ferreira
CCC.C. Carias
C.C. Carias
JNJ.M. Novais
J.M. Novais
SMS. Martins-Dias
S. Martins-Dias

22 January 2008 in Biopolymers
Verified
Journal Article
Closed access
PDF file
RBRicardo P. Baptista
Ricardo P. Baptista
Shona Dr. Shona PedersenShona Dr. Shona Pedersen
Shona Dr. Shona Pedersen
GCGonçalo J. M. Cabrita
Gonçalo J. M. Cabrita
DODaniel Otzen
Daniel Otzen
Joaquim M.S. CabralJoaquim M.S. Cabral
Joaquim M.S. Cabral
Eduardo MeloEduardo Melo
Eduardo Melo

1 August 2005 in Journal of Molecular Biology
Verified
Journal Article
Closed access
LCLuYang Chen
LuYang Chen
GCGonçalo J.M. Cabrita
Gonçalo J.M. Cabrita
DODaniel Otzen
Daniel Otzen
Eduardo MeloEduardo Melo
Eduardo Melo